Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
2.520
+0.100 (4.13%)
At close: Aug 13, 2025, 4:00 PM
2.500
-0.020 (-0.79%)
Pre-market: Aug 14, 2025, 8:52 AM EDT
Revelation Biosciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Revelation Biosciences.
Price Target: $0.00 (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Revelation Biosciences.
Recommendation Trends
Rating | Dec '22 | Jan '23 | Feb '23 |
---|---|---|---|
Strong Buy | 1 | 1 | 0 |
Buy | 0 | 0 | 0 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 1 | 1 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Roth MKM | Roth MKM | Strong Buy Maintains $7,200 → $21,600 | Strong Buy | Maintains | $7,200 → $21,600 | +857,042.86% | Feb 14, 2023 |
Roth Capital | Roth Capital | Strong Buy Initiates $604,800 | Strong Buy | Initiates | $604,800 | +23,999,900.00% | Feb 17, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-14.48
from -263.05
EPS Next Year
-5.94
from -14.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -8.76 | -6.11 | -5.83 | ||
Avg | -14.48 | -5.94 | -5.66 | ||
Low | -19.65 | -5.70 | -5.44 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.